[Question] glucagon — what am I missing here
The title is the whole question — glucagon — what am I missing here — but here is why I am asking. It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards…
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.
Disagree — that is a weight endpoint from a different programme and you are quoting it in a hepatic context.
Disagree — that is a weight endpoint from a different programme and you are quoting it in a hepatic context.
Disagreeing with this bit: that number comes from a different programme with a different population.
Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.
Agreed that the endpoint definitions matter enormously and almost nobody reads them before quoting a response rate.
phase 2 in liver disease is a different evidence question from weight
dual GLP-1 and glucagon agonist, and the glucagon arm is the story
dual GLP-1 and glucagon agonist, and the glucagon arm is the story
Agreed — and the endpoint definitions are where the actual claim lives.